

Special Issue

New Technologies Used to Diagnose and Treat Lymphomas

Message from the Guest Editor

We are pleased to invite you to submit original articles or reviews on lymphomas, one of the most common cancers in the world. There are different types of lymphomas with varied patterns of clinical behavior, prognosis, and responses to treatment. In recent years, new therapeutic strategies have been used and new diagnostic tools have been found, especially using artificial intelligence for diagnoses and treatment responses. However many studies are still needed to optimize diagnostic and therapeutic tools. This Special Issue aims to showcase new therapeutic strategies increasingly targeted towards the individual patient. In addition, new tools are being used for diagnosis and response to treatments, both from a molecular and imaging perspective, with particular reference to PET/CT and MRI. In this setting, we must not forget artificial intelligence, a new and increasingly fundamental tool used in the diagnostic and therapeutic pathway of lymphomas. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: nuclear medicine, radiology, hematology, immunotherapy, and radiotherapy.

Guest Editor

Dr. Ambra Buschiazzo

Nuclear Medicine Division, Santa Croce and Carle Hospital, 12100 Cuneo, Italy

Deadline for manuscript submissions

closed (20 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/200505

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)